Skip to main content
. 2014 May;6(Suppl 3):S341–S349. doi: 10.3978/j.issn.2072-1439.2014.03.29

Table 5. Non-randomized phase II trials utilizing selective surgery.

Reference; [Study interval] Patients N Histology Endpoints Results
Wilson and Lim; [1993-1996] (31) T1-3, N0-1, M0 32 SCCA/ACA Path response, survival, organ preservation, toxicity Endoscopic response 77%, selective approach was feasible
Ariga et al.; [2001-2005] (32) T1-3, N0-1, M0 99 SCCA OS, DFS, QOL, toxicity 26% cross-over to salvage surgery
Swisher et al.; [2003-2006] (33) T1-3, N0-1, M0-1a 41 SCCA/ACA Treatment response, organ preservation, toxicity, feasibility 1-yr survival goals not met, but feasibility demonstrated

SCCA, squamous cell carcinoma; ACA, adenocarcinoma; OS, overall survival; DFS, disease free survival; QOL, quality of life.